Close Menu


Microbiotica, Cambridge University, and Cancer Research UK will develop microbiome co-therapeutics and gut bacteria signatures for predicting immunotherapy response.

The collaboration will test the effects of using human microbiome-derived bacteria alongside immune checkpoint inhibitor nivolumab to treat advanced metastatic cancers.

Researchers have shown that the use of antibiotics in the weeks leading up to immunotherapy may lessen a patients' response to the treatment.